Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No concerns that is data on only 7 patients ?
It is obvious that this is will be an attack line for the likes of AF, JF,...
Though powered with an adaptive trial, they do not understand or refuse to understand it and hence keep hitting the same nail.
Who is this guy ?? For all we know this is just a fraud or fake.
So we agree they key is education. Exactly what has been missing in big pharma. Stuck in a tunnel vision, not realising it leads to nowhere.
Just think how shocking it was to say the world was round. It got Galileo into quite some trouble before it was accepted.
Same with Anavex. Too many big pharma and established theories are made to look foolish.
thanks for your detailed analysis!
put in my stink bid of trading shares at 3.62 and got triggered :)
There are several phase 2 trials ongoing with major institutes, DOD grant given, high institutional ownership, combotrial with AstraZeneca...
Would can one want more?
Daily share price means nothing. It's the long game that matters.
Incompetent management or incompetent shareholders are both not a crime.
What would you sue them for?
Misslijg definatly sounds as German as one can. Like this guy:
What are you sinking about
Nein das ist nicht richting: herr doctor Missling is ein Deutscher.
Would he not be better off in NY at the crossing of 5th Av and 56st?
We saw the latter seconds after the PR was released with 31week data and the first we can observe again.
I think the PR was released to prevent a pre-conference framing, as AF did in July. We were lucky to preceed LLY.
AF had no clue, he was trying to frame the mindsets.
Perhaps we are a bit protected as everybody's attention this week is on ASH
Institutional ownership is at 12,83%
And any share price predictions?
I for one have no intention to dump my shares seconds after the PR release!
Who is this source ?
The guy has 38 tweets, follows 25 people and has 35 followers...
And we do not have high institutional ownership, and we have seen that volatility before! However, not such a run this time, unless it happens this week.
One week to buy, hold or dump shares. Quick, only seconds to decide ones the PR is out!
Great so now we are already at q3 2017 FDA approval...
Feels very similiar to the talk last July or November!
Also he is applying phase 3 criteria to a phase 2a trial.
No matter what, he will hate us until he cannot deny it any longer. Look at LLY, even with a triple phase 3 failure he is still pushing them.
So what slot would be gamechanging?
In that case, you have overlooked posts 81468 and 81479.
You think it wise for a conference organisation to play these kind of games?
Yeah the fund me page was hilarious.
I hope we can break their power with a partnership. However, they are leading the score by 2-0...
Now idea on the way. However last years roundtable did not change anything for Anavex. Let's hope we can make more heads turn this year.
Missling goes back to the Capitol. Hopefully this time it will do more for us.
NEW YORK, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today announced that Christopher U. Missling, Ph.D., President and Chief Executive Officer, will participate on a panel comprising 14 representatives from government and industry at the Fourth Annual Mental Health Parity and Addiction Equity Act (MHPAEA) Business Roundtable. The panel members will discuss the current challenges around implementation of the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 and an action plan. The event will take place on Tuesday, December 6, 2016, at the U.S. Capitol Visitor Center, in Washington, D.C.
Why exactly they pr'ed 41 weeks is unknown but sure as hell this is Missling trying to communicate to his shareholders, as he did in June '15 with his small purchases. He has said as much as his lawyers and CTAD would allow him.
Out of experience: trade your plan, do not let greed take the better of a good plan!
But real cash, no biobucks as AF stated today
What is sure is that a phase 1, to establish the safety profile, is not required.
Unless they would go beyond the current tested dosages.
As Missling stated before: partner up for the Alzheimer p3 and use that cash to do the Rett and others on your own.
All time high shareprice by end of the week? month? year?
No need to scare away investors as the patent issue has been covered.
BIIB is bound to fail, amyloid plaque hypothesis too.
LLY is the third time this drug fails a p3.
How many times does it need to fail before big pharma gives up on a theory?
He did not show his market saviness last November or this July.
But it seems he has learned, so that is a good thing! Hope it works :)
the piano player, the painter, the golfer,
Oh so no split hair fraction of a second to decide wether or not to dump this stock??
You would think so.
But given how many years and mighty dollars have been spent on the amyloid plaque theory, and especially the lack of results, I am afraid big pharma is just too pigheaded to let it go.
We can only hope to further increase the institutional ownership!